Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndromes

Area of Science:

• Cardiology
• Clinical Medicine
• Inflammation Research

Background:

• Low lymphocyte count (LLC) is linked to inflammation and adverse cardiovascular outcomes.
• Identifying optimal treatment strategies for high-risk non-ST segment elevation acute coronary syndromes (NSTEACS) is crucial.
• The benefit of invasive revascularization strategy versus conservative strategy in NSTEACS patients with LLC is not well-defined.

Purpose of the Study:

• To evaluate if high-risk NSTEACS patients with LLC experience a greater reduction in long-term post-discharge myocardial infarction (MI) with an invasive revascularization strategy (RIS) compared to conservative strategy (CS).

Main Methods:

• A total of 972 high-risk NSTEACS patients were analyzed.
• Patients were treated with either CS (n=345) or RIS (n=627).
• LLC was defined as lymphocyte count <= 1200 cells/ml. Cox regression was used to assess the association between revascularization strategy and MI, stratified by LLC status.

Main Results:

• At 3-year follow-up, 13.9% of patients experienced MI.
• In multivariable analysis, patients with LLC showed a significantly greater reduction in MI risk with RIS (HR: 0.40; p=0.003).
• No significant difference in MI rates was observed between RIS and CS in patients without LLC.

Conclusions:

• LLC identifies a specific subgroup of NSTEACS patients who benefit from an invasive revascularization strategy.
• RIS leads to a greater reduction in post-discharge MI risk for NSTEACS patients with LLC.
• The findings support personalized treatment approaches based on inflammatory markers in acute coronary syndromes.